CA 19-9, or carbohydrate antigen 19-9, is a glycoprotein produced by certain epithelial cells of the digestive tract and bile ducts. An elevated serum level does not automatically indicate cancer: this marker increases in several benign pathologies, making it a tool for monitoring rather than a reliable standalone screening test.
Cholestasis and biliary pathologies: the most common benign cause of elevated CA 19-9
The mechanism most often responsible for an isolated elevation of CA 19-9 is a slowdown or blockage of bile flow. When bile does not flow normally, the glycoprotein accumulates in the blood instead of being excreted.
This is why an obstructive gallstone or inflammation of the bile ducts (cholangitis) can cause the marker to rise to sometimes very high values, without any tumor being involved. The same phenomenon is observed during jaundice, regardless of its origin.
Interpreting a CA 19-9 test performed during jaundice or active liver disease can lead to erroneous conclusions. Several recent recommendations emphasize the need to recheck the level after the biliary obstruction is resolved or after treatment of cholestasis.
If the value decreases significantly, the benign cause is confirmed. To better understand why CA 19-9 may be elevated in these situations, the dynamics of the marker over time remains the most discriminating factor.
Pancreatitis and chronic digestive diseases: sometimes lasting elevations
Acute and chronic pancreatitis are among the classic causes of an elevated CA 19-9. Inflammation of pancreatic tissue stimulates the secretion of this glycoprotein, and repeated flare-ups can maintain a moderately high level over several months.
Other digestive conditions cause the same type of elevation:
- Diffuse liver diseases, such as cirrhosis or active hepatitis, disrupt the metabolism of the marker and reduce its hepatic clearance
- Some inflammatory bowel diseases (Crohn’s disease, active ulcerative colitis) increase epithelial production of CA 19-9
- Benign pancreatic cysts, particularly mucinous cystadenomas, sometimes secrete the marker at significant levels without malignant transformation
In all these cases, the level generally remains lower than in advanced pancreatic cancer. The difficulty lies in the overlapping areas, where only imaging and longitudinal follow-up can provide clarity.
CA 19-9 and cancers: when the marker points to a tumor
CA 19-9 was first identified in connection with pancreatic cancer, which remains the malignant condition most often associated with a significant elevation. Other digestive cancers also raise this marker: biliary tract cancers (cholangiocarcinomas), gastric cancers, and, to a lesser extent, colorectal cancers.
Some extra-digestive cancers can also cause an increase, notably certain mucinous ovarian cancers and, more rarely, lung cancers. These situations are minority cases but remind us that CA 19-9 is not specific to one organ.
Limitations of the marker in a tumor context
INCa recommendations regarding pancreatic adenocarcinoma include CA 19-9 in the initial assessment and post-therapeutic follow-up, but not as a standalone screening tool. The marker misses early cancers and produces false positives in benign conditions, which limits its positive predictive value in asymptomatic individuals.
In clinical practice, CA 19-9 is mainly used for two purposes: to assess the response to treatment of an already diagnosed cancer and to detect a recurrence during follow-up. A decrease during chemotherapy is correlated with a better prognosis, while a rise can signal a return of the disease even before imaging shows a visible lesion.
Monitoring CA 19-9: trend matters more than isolated value
A single CA 19-9 test has limited value. Recent medical content converges on a simple rule: comparing successive tests in the same laboratory provides much more reliable information than a number taken out of context.
A slightly elevated level, stable over time, suggests a chronic benign cause (liver disease, digestive inflammation). A rapid rise over several weeks or months, even from an initially normal value, justifies further investigations.
Another important point to know: a fraction of the population does not secrete CA 19-9 due to their Lewis blood group. In these individuals, the marker remains low even in the presence of advanced pancreatic cancer. Therefore, a normal level is never sufficient to exclude a diagnosis.
Interpreting a CA 19-9 result always requires cross-referencing with clinical context, imaging, and other biological tests. An elevated marker triggers a diagnostic process, not a diagnosis in itself. This distinction remains the most misunderstood point by patients who discover an abnormal result on a routine test.